Veliparib (ABT-888)

製品コードS1004 別名:NSC 737664

Veliparib (ABT-888)化学構造

分子量(MW):244.29

Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.

サイズ 価格(税別)  
JPY 27800
JPY 21900
JPY 63400
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(60)

製品安全説明書

PARP阻害剤の選択性比較

生物活性

製品説明 Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.
特性 Increases the efficacy of common cancer therapies such as radiation and alkylating agents.
ターゲット
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
2.9 nM(Ki) 5.2 nM(Ki)
体外試験

ABT-888 is inactive to SIRT2 (>5 μM). [1] ABT-888 inhibits the PARP activity with EC50 of 2 nM in C41 cells. [2] ABT-888 could decrease the PAR levels in both irradiated and nonirradiated H460 cells. ABT-888 also reduces clonogenic survival and inhibits DNA repair by PARP-1 inhibition in H460 cells. ABT-888 increases apoptosis and autophagy in H460 cells when combination with radiation. [3] ABT-888 also inhibits PARP activity in H1299, DU145 and 22RV1 cells and the inhibition is independent of p53 function. ABT-888 (10 μM) suppresses the surviving fraction (SF) by 43% in the clonogenic H1299 cells. ABT-888 shows effective radiosensitivity in oxic H1299 cells. Furthermore, ABT-888 could attenuate the SF of hypoxic-irradiated cells including H1299, DU145 and 22RV1. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
C41 NIPMVIpMcW6jc3WgRZN{[Xl? MoflN|AhdWmw M37He2lvcGmkaYTpc44hd2ZiUFHSVFEhf2m2aDDFR|UxKG:oIECuNFAzKM7:TR?= MXSxPVg5QDd4MB?=
Jurkat M4\4N2tqdmG|ZTDBd5NigQ>? NHrqW4g6PiCq MoPiSG1UVw>? M3TZbWlvcGmkaYTpc44hd2ZiUFHSVFEh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJINmdGxidnnhZoltcXS7IIfpeIghTUN3MDDv[kA{KM7:TR?= NWLCR3NFOjN6NUCxPVk>
Capan1 NXnSSVQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPPVYw4OiCq NVPuXXQyTE2VTx?= MlzQRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDCVmNCOiCpZX7lJI12fGG2ZXSgbJVu[W5iQ3HwZY4yKGOnbHzzJJdqfGhiSVO1NEBw\iB|OT63JO69VQ>? M3z6eFI1Ozl6M{iz
DT40 MWjDfZRwfG:6aXOgRZN{[Xl? M1XxOVczKGh? MljLSG1UVw>? NXy3VIhIS3m2b4TvfIlkcXS7IHHnZYlve3RiY3jpZ4tmdiCEUlPBNk1l\W[rY3nlcpQhTFR2MDDj[Yxtew>? M{GyUlI1QTJ{NUi3
ML-1 NFWzb|dCeG:ydH;0bYMhSXO|YYm= MWmyMlUh|ryP M3LZO|I1KGh? MnTaSG1UVw>? NI\lcVNUgW6ncnfpd5Rq[2GubImg[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXNiaX6gUWwuOSClZXzsdy=> NGP5VFEzPDh7NUGzOS=>
HCT-116 NVuwPYo6U2mwYYPlJGF{e2G7 M1PxWFAvPSEQvF2= MX[yOEBp NInLV2FRSVKSIHHjeIl3cXS7IHTlZ5Jm[XOncx?= MkXINlMxPTR{MUO=
UM-SCC1 NXL1[ItJS3m2b4TvfIlkKEG|c3H5 MYixNEDPxE1? M4q1ZlI1KGh? NXvRSFFtWmWmdXPld{B1cGViY3XscEB3cWGkaXzpeJk> M{\YclIyQTF{NkKw
FaDu MWDDfZRwfG:6aXOgRZN{[Xl? NVHjR3llOTBizszN M3;5SVI1KGh? Mnf6VoVlfWOnczD0bIUh[2WubDD2bYFjcWyrdIm= MlXqNlE6OTJ4MkC=
PC-3 MnHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYS2d5RTOTBizszN NX3WTGZ[UW6mdXPld{BiKHOrZ37p[olk[W62IHnubIljcXSrb36gbY4h[2:ub375JIZwem2jdHnvcuKh MUWyNVU4OTlzMh?=
EoL-1-cell M4TZ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTFwMEe5PEDPxE1? NYXUS3RxW0GQR1XS
NCI-SNU-5 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTNwMUK4OFEh|ryP NID5WpZUSU6JRWK=
BV-173 NFWwXHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTVwNEW0NFkh|ryP NWnUO41SW0GQR1XS
HCC1806 NYG1Soc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvJTWM2OD13Lke1NVc{KM7:TR?= MWDTRW5ITVJ?
COLO-680 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mke5TWM2OD14LkKxOFA3KM7:TR?= Mmf3V2FPT0WU
HCC2218 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTdwN{m3NFQh|ryP M4nBUXNCVkeHUh?=
SK-MEL-24 NV;jW|dQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\vXGFOUUN3ME23MlgyQTJ2IN88US=> M2KyVHNCVkeHUh?=
NCI-H720 NUDhcIU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfOSpBKSzVyPUiuOFM3ODNizszN M1zw[3NCVkeHUh?=
KASUMI-1 M2jweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;zeXF7UUN3ME24Mlg6OjZ4IN88US=> NUXZdJVRW0GQR1XS
HAL-01 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPrTWM2OD17Lki4OlIh|ryP M3\1WnNCVkeHUh?=
CAL-33 NUnxc29nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmP5TWM2OD1zMD60N|Qh|ryP M4\jbXNCVkeHUh?=
SK-MEL-1 NHjlNGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjQPHBKSzVyPUGyMlQ3PjNizszN NH\NPGNUSU6JRWK=
Ramos-2G6-4C10 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HrRWlEPTB;MUKuOFc2OiEQvF2= NVHDZXR4W0GQR1XS
KY821 NXrPR|BkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXrNpRSUUN3ME2xNk41QDVizszN MoDwV2FPT0WU
HEC-1 MnTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYO2eZhPUUN3ME2xNk46OTl4IN88US=> MknvV2FPT0WU
SK-NEP-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTF|LkG2OkDPxE1? NGnDfG9USU6JRWK=
MN-60 M3zCWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnURndKSzVyPUGzMlU{QDlizszN Mnf0V2FPT0WU
DU-145 M1LPT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfBfXdKSzVyPUGzMlkxPTNizszN MXHTRW5ITVJ?
EW-3 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTF2LkW1OlUh|ryP NU\aSHg6W0GQR1XS
OS-RC-2 M3HlcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTGXWZKSzVyPUG1Mlk2QDlizszN MnTiV2FPT0WU
RPMI-8226 NUHrbXdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUX2bHdnUUN3ME2xOk4zODR{IN88US=> M{\US3NCVkeHUh?=
ChaGo-K-1 NWjJ[WhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTF4LkWzNlUh|ryP Mn33V2FPT0WU
DEL MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjaN|E4UUN3ME2xOk43PzF5IN88US=> NGfoXXNUSU6JRWK=
GP5d MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTF5LkC1N{DPxE1? NX;wfWFwW0GQR1XS
COLO-668 NGjDcIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXYTWM2OD1zNz62Nlk1KM7:TR?= MYDTRW5ITVJ?
H9 Mli1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\yXolKSzVyPUG4MlI5OzNizszN NGfWTGtUSU6JRWK=
NKM-1 MoDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vTd2lEPTB;MUiuOVEyQSEQvF2= MVzTRW5ITVJ?
KYSE-150 NYLMUpFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGG5T|JKSzVyPUG4Mlk6QDZizszN M2fkT3NCVkeHUh?=
Daoy NHTVZmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTF7LkW2OFkh|ryP MVzTRW5ITVJ?
ECC10 M{nEfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrPTWM2OD1{MD63OFU2KM7:TR?= NHfjZXVUSU6JRWK=
A388 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLVTWM2OD1{MT65NFkyKM7:TR?= MoWxV2FPT0WU
MHH-NB-11 NXLKem1ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37Lb2lEPTB;MkOuNVM3OyEQvF2= NHqzZYxUSU6JRWK=
HCC1937 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXMW|QzUUN3ME2yOE44PDZizszN NWfLVlF[W0GQR1XS
TGBC11TKB M13vRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrZNW9KSzVyPUK1MlY5PjNizszN NWm2UnlnW0GQR1XS
CTV-1 Mk\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Li[2lEPTB;MkWuPFk3QSEQvF2= NHe3[oZUSU6JRWK=
NCI-H2029 NW\WXIt4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPKTWM2OD1{Nj60NlM5KM7:TR?= NILico1USU6JRWK=
HLE MnXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTJ5LkC1OEDPxE1? MUPTRW5ITVJ?
NCI-H1693 MoHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vWb2lEPTB;MkeuNlg6QCEQvF2= MlPtV2FPT0WU
HCC70 MlHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\RTWM2OD1{Nz63NlQ3KM7:TR?= Mnj5V2FPT0WU
BEN Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\aTWM2OD1{Nz65OVY3KM7:TR?= M1XDU3NCVkeHUh?=
LB771 M1W2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTJ6LkizO|Mh|ryP MlXGV2FPT0WU
697 M1\abWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7OTWM2OD1{OT6wNlM2KM7:TR?= MX3TRW5ITVJ?
LU-139 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fL[mlEPTB;MkmuN|c1QCEQvF2= NGLEV5RUSU6JRWK=
EW-13 NWTRU3dDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEW2XHpKSzVyPUK5MlM5OTRizszN MYDTRW5ITVJ?
MOLT-13 NIjp[lZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;YTWM2OD1{OT6zPFE1KM7:TR?= NFGwV2VUSU6JRWK=
L-363 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTJ7LkS3PVgh|ryP NWH4XWN4W0GQR1XS
EM-2 MnnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTObGVKSzVyPUK5MlQ6ODFizszN M33MVHNCVkeHUh?=
RS4-11 M4C0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vlZ2lEPTB;M{CuOFI1OSEQvF2= M2X0R3NCVkeHUh?=
A2780 M2ewTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzQXZBKSzVyPUOwMlc1PTdizszN MojvV2FPT0WU
KU812 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HLUWlEPTB;M{KuN|Y1OiEQvF2= NVvicJprW0GQR1XS
COLO-684 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTN|LkO1PVkh|ryP NWHHeGZGW0GQR1XS
MFE-280 M{W0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHtTWM2OD1|Mz6zPFg6KM7:TR?= MlfIV2FPT0WU
KG-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkW1TWM2OD1|Mz62NFAyKM7:TR?= M13WR3NCVkeHUh?=
JVM-3 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTN3LkW4Olgh|ryP M1\XWHNCVkeHUh?=
MV-4-11 NUfIXJFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTN3Lki0PVkh|ryP NFf4O3lUSU6JRWK=
LAMA-84 NEjGUZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXr1d25JUUN3ME2zOk44OzR3IN88US=> NGK5VWdUSU6JRWK=
MOLT-16 M1GzOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{f0VWlEPTB;M{[uPVUzKM7:TR?= NF7EfmtUSU6JRWK=
H4 Ml3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4f0SWlEPTB;M{euOVY4KM7:TR?= MUnTRW5ITVJ?
T47D MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEC4OIpKSzVyPUO3MlcxOThizszN MYnTRW5ITVJ?
CAL-54 M2\sd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnjfWZKSzVyPUO3Mlk3PiEQvF2= MWjTRW5ITVJ?
SW982 NGXxTJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDzc4xKSzVyPUO4MlA6QThizszN NX7kUZk3W0GQR1XS
IGROV-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvxZnl4UUN3ME2zPU4{OzB2IN88US=> NIX5cohUSU6JRWK=
NB14 NUTt[pc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;jTWM2OD12MD63NFMyKM7:TR?= NX\VellDW0GQR1XS
HCC1187 MojSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInKeodKSzVyPUSxMlI4PzFizszN MUDTRW5ITVJ?
SBC-1 NUDseI5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWK0UG5qUUN3ME20NU4{ODZ|IN88US=> NXnZd2tNW0GQR1XS
KARPAS-45 NGnyWFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTjTWM2OD12MT60PFE5KM7:TR?= NVy1NpBiW0GQR1XS
MOLT-4 M1jEdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHYb5lKSzVyPUSyMlI2OzhizszN MmHVV2FPT0WU
JVM-2 NH;YdZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPJS4RKSzVyPUSyMlkzODdizszN NWTQZm42W0GQR1XS
A4-Fuk NIfmSnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\JTVlJUUN3ME20N{42PjlzIN88US=> MULTRW5ITVJ?
MDA-MB-361 M3PtWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHac5J7UUN3ME20N{45PDF2IN88US=> M4XkfnNCVkeHUh?=
BALL-1 M4HkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnwOHFKSzVyPUSzMlk2OzJizszN MlnTV2FPT0WU
T98G MlzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3u5Z2lEPTB;NESuPFUyPyEQvF2= NIjmXFRUSU6JRWK=
Mo-T MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTR3Lk[zPFkh|ryP M2r0[HNCVkeHUh?=
MHH-PREB-1 NGXrRo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWH3[pgxUUN3ME20OU44PTh3IN88US=> NYHxbpRnW0GQR1XS
ALL-PO M4n4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33TcWlEPTB;NEeuN|c6OSEQvF2= MmCxV2FPT0WU
NCI-H510A NXLMeZhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITFXGVKSzVyPUS3MlkxOzRizszN NYLvUY8xW0GQR1XS
ML-2 NGnRSpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rJUmlEPTB;NEmuO|g2PiEQvF2= Ml70V2FPT0WU

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
p-STAT3 / STAT3 / p-AKT(S473) / p-AKT(T308) / p-ERK / p-p38; 

PubMed: 22678161     


Effects of AG-014699, AZD-2281, ABT-888, or BSI-201 on the phosphorylation status of Stat3, Akt, ERK, and p38 in MDA-MB-468, MDA-MB-231, and Cal-51 cells after 72 h of treatment

22678161
Immunofluorescence
HuR; 

PubMed: 28687616     


Immunofluorescent images of HuR (green) in MIA PaCa-2 cells treated with PARPi for 12hr. Nuclei were stained with DAPI. Magnification 40X.

BRCA1; 

PubMed: 21917757     


Effects of ABT-888 and/or bortezomib on BRCA1 and RAD51 foci formation. BRCA1 and RAD1 foci induced by ABT-888 were completely resolved in cells cotreated with bortezomib. Image acquisition was performed with an epifluorescence microscope (BX51; Olympus) and multispectral color camera (Nuance FX; CRi) with a 60× or 100× magnification lens and oil immersion.

28687616 21917757
Growth inhibition assay
Cell viability (TNBC cell lines); 

PubMed: 27880910     


BRCA-proficient TNBC cell lines were treated with veliparib in the absence and presence of dinaciclib, demonstrating reduced IC50 values in the presence of dinaciclib.

Cell viability (melanoma cells); 

PubMed: 29956724     


Dose-dependent inhibitory effect of ABT-888 on melanoma cell proliferation. Human melanoma cell lines were exposed to diluents (control; CTRL) or increasing concentrations of ABT-888 for 72 h and their viability was assessed by MTT assay. Absorbance was detected at 540 nm with a microplate reader and data were expressed as a percentage of the CTRL. Data are the means ± SD of 3 experiments performed in triplicate. Statistical significance was calculated against the CTRL (*P<0.05; **P<0.01).

27880910 29956724
体内試験 The oral bioavailability of ABT-888 is 56%-92% in mice, Sprague-Dawley rats, beagle dogs, and cynomolgus monkeys after oral administration. [1] ABT-888 (25 mg/kg i.p.) could improve tumor growth delay in a NCI-H460 xenograft model with well tolerated. Combination with radiation, ABT-888 decreases the tumor vessel formation. [3] ABT-888 reduces intratumor PAR levels by more than 95% at a dose of 3 and 12.5 mg/kg in A375 and Colo829 xenograft models and the suppression could be maintained over time. [4]

お薦めの試験操作(参考用のみ)

動物試験:

[1]

+ 展開
  • 動物モデル: NCI-H460, H460, B16F10 and 9L xenografts in C57BL/6 mice
  • 製剤: Formulated in solution containing 0.9% NaCl adjusted to pH 4.0
  • 投薬量: ~25 mg/kg
  • 投与方法: Orally administered
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 17 mg/mL (69.58 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
0.5% methylcellulose+0.2% Tween 80
混合させたのち直ちに使用することを推奨します。
5 mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 244.29
化学式

C13H16N4O

CAS No. 912444-00-9
保管
in solvent
別名 NSC 737664

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03400306 Not yet recruiting Cancer - Ovarian AbbVie May 10 2020 Phase 1
NCT03400306 Not yet recruiting Cancer - Ovarian AbbVie May 10 2020 Phase 1
NCT03044795 Not yet recruiting Cancer University Medical Center Groningen|AbbVie|Dutch Cancer Society November 2018 Phase 2
NCT03044795 Not yet recruiting Cancer University Medical Center Groningen|AbbVie|Dutch Cancer Society November 2018 Phase 2
NCT03581292 Recruiting Anaplastic Astrocytoma|Glioblastoma|Malignant Glioma National Cancer Institute (NCI) October 31 2018 Phase 2
NCT03581292 Recruiting Anaplastic Astrocytoma|Glioblastoma|Malignant Glioma National Cancer Institute (NCI) October 31 2018 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

PARPシグナル伝達経路

PARP Inhibitors with Unique Features

相関PARP製品

Tags: Veliparib (ABT-888)を買う | Veliparib (ABT-888) ic50 | Veliparib (ABT-888)供給者 | Veliparib (ABT-888)を購入する | Veliparib (ABT-888)費用 | Veliparib (ABT-888)生産者 | オーダーVeliparib (ABT-888) | Veliparib (ABT-888)化学構造 | Veliparib (ABT-888)分子量 | Veliparib (ABT-888)代理店
×

平素は格別のお引き立てを賜り厚くお礼申し上げます。
国内在庫の無い製品の輸入手配は通常、毎週木曜12時で締め切らせていただいておりますが、
9月第2週の輸入手配に関しましては都合により締切日を9月10日(火)12時とさせていただきます。
お客様には大変ご不便をお掛けいたしますが、よろしくお願い申し上げます。

×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID